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Abstract 
 Background: Globally, sexually transmitted infections (STIs) in women are 
associated with significant morbidity and mortality. Challenges to prevention and control 
of STIs remain their asymptomatic nature, poor screening and treatment algorithms and 
poor access to screening and treatment services, especially in developing countries. While 
associations between most pairs of STIs are established, few studies have examined the 
clustering of more than two STIs in women, despite the implications for prevention and 
treatment.  
Methods: This study uses baseline data from 350 female sex workers in Korogocho, 
Kenya, collected between 2009 and 2011, to examine the clustering of more than two STIs 
among chlamydia, gonorrhea, HIV, human papillomavirus, mycoplasma and 
trichomoniasis, and the correlates of multiple STIs. The secondary objective of this study is 
to highlight the utility of propensity scores and machine learning methods (boosted 
classification and regression trees and covariate balancing propensity scores) in estimating 
treatment effects from data with rare outcomes in maternal and child health research. 
 Results: Having more than two concurrent STIs is relatively uncommon. Although 
HIV and human papillomavirus infection was initially significantly associated with 
trichomoniasis co-infection, this association became insignificant after balancing on the 
propensity score. This effect was homogenous irrespective of the method of propensity 
score estimation and application. There were no demographic or behavioral correlates of 
having multiple concurrent STIs, although the number of daily sex partners nearly reached 
statistical significance.  
 Summary: Multiple concurrent STIs are uncommon and HIV, HPV and 
trichomoniasis do not seem to cluster. Larger cross-sectional sample should be used to 
revalidate these findings and examine the associations between other STIs. Estimating 
treatment effects from data with rare outcomes and multiple confounders remain 
challenging, particularly when cross-sectional studies are the only ethical means available 
to conduct such studies. This is an area of maternal and child health research where 
propensity score analysis can help reduce bias in study results. 
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Introduction 
 The World Health Organization estimates that there are approximately 500million 
incident cases of chlamydia, gonorrhea, syphilis and trichomoniasis every year. 1 Sexually 
transmitted infections (STIs) in women are among the leading causes of disability adjusted 
life years, especially in developing countries. 2 For example, 275,000 women die from 
cervical cancer each year as a result of persistent infection with the Human Papillomavirus 
(HPV), and up to 85% of women seeking care for infertility in Sub-Saharan Africa (SSA) 
have tubal complications arising from untreated chlamydia and gonorrhea infections.3 
Further, 305,000 fetal and neonatal deaths are attributable to congenital syphilis infection.3  
 The burden of curable STIs is high in many low-income countries, where 
availability of, and access to preventive and curative services is poor, and the referral and 
follow-up systems for testing, treatment and partner notification are weak. In addition, the 
stigma associated with STIs prevents many women from testing and seeking treatment. 3-7 
The fear of loss of a relationship or intimate partner violence, especially in patriarchal 
societies is also a significant barrier to STI testing uptake and disclosure of positive test 
results to sexual partners for many women. 5,6 Furthermore, a large proportion of STIs in 
women are asymptomatic, making detection difficult and increasing the potential for 
spread to other sexual partners. 2,3,8   
Over the past two decades, the focus of public health interventions relating to STIs 
has been centered on HIV prevention and treatment, marginalizing other STIs, despite their 
documented association with an increased risk for HIV transmission. 2,3 For example, there 
exists at least a three-fold increased risk of HIV acquisition in individuals who are positive 
for syphilis or Herpes Simplex 2 virus (HSV-2) infection. 2,3,9,10 Also, genital ulcer diseases 
including lymphogranuloma venereum and those caused by Hemophilus ducreyi, as well 
as STIs that cause cervical inflammation (chlamydia, gonorrhea) have been associated with 
an increased risk for HIV transmission. 2,9-14 Fastring et al have also documented the 
association between trichomonas infection and increased shedding of HIV-1 RNA. 15 HIV 
infection increases the risk for the acquisition of other STIs primarily by suppressing the 
immune system, often leading to a higher incidence and severity for other STIs, especially 
HPV infection and cervical cancer. Recently, Lissouba et al found in a systematic review 
and meta-analysis of six observational studies, that individuals with HPV infection were 
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almost twice as likely to acquire a HIV infection. 16 Similar findings have been 
demonstrated in studies among men. 17   
Chlamydia, gonorrhea, syphilis, trichomonas and mycoplasma among others, are 
curable STIs, sometimes with inexpensive antibiotics (e.g. penicillin for Syphilis). Anti-
retroviral medications (ARVs) are also effective in preventing immune suppression in HIV 
positive individuals and in reducing reactivation and active disease in individuals who 
already have had primary HSV infection 18-21.  
Despite these known remedies, the diagnosis of STIs in women is challenging. The 
WHO recommends syndromic management in settings where laboratory testing is not 
available or cost effective. 1,3 As such, individuals with suspected gonorrhea infection are 
often given treatment for chlamydia as well. Thus, determining which specific STIs to be 
screened for, or treated in women presenting at an STI treatment facility requires a sound 
evidence base of the specific STIs that tend to cluster. This is the primary aim of this paper.  
While numerous studies have assessed which pairs of STIs historically cluster, the 
evaluation of women for just two concurrent STIs may be a missed opportunity for the 
identification of a third infection; it may also increase the morbidity associated with the 
undetected third STI. Cost effectiveness of STI screening can also be improved by 
developing clinical screening guidelines for specific infections in women presenting with 
symptoms of other STIs. In addition, vaccine development for multiple sexually transmitted 
infections will rely on epidemiologic studies that have documented which STIs tend to 
cluster in individuals. 
Multiple STIs (i.e. having more than two concurrent infections) remain relatively 
uncommon. 22,23 Ethical guidelines also prohibit following women with treatable STIs 
longitudinally (while denying them the current standard of care) for the purpose of studying 
which additional infections they develop. Cross-sectional studies may therefore be the only 
feasible alternative for studying multiple concurrent STIs in women. Given that these are 
relatively rare events, there are methodological challenges associated with these types of 
studies. 24,25 
This study aims to explore which specific STIs cluster in women at the individual 
level and to highlight the utility of machine learning methods when outcomes are rare in 
maternal and child health research. 25 The results will be useful in guiding the screening 
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and treatment of sexually transmitted infections in women, especially in resource poor 
settings.  
 
 
Methods 
Study Population 
The data come from the baseline observation of 350 female sex workers (FSWs) 
attending an STI clinic in Korogocho, Nairobi Kenya between August 2009 and March 
2011.  Participants were aged 18-49 years and were followed up at three monthly 
intervals. The clinic provides counseling and medical care including screening and 
treatment of cervical cancer and sexually transmitted infections. Women were not eligible 
for enrollment into the study if they had undergone a hysterectomy or were in the second 
trimester of pregnancy. All participants provided written informed consent. Women with 
missing information on any of the covariates, dependent and independent variables were 
excluded from the analysis, leaving 334 women in the final sample. 
 
Sample Collection 
Each woman self-collected a cervico-vaginal specimen using a cytobrush following 
a graphical instruction sheet. The cytobrush was then placed into the Aptima® 
(Hologic/Gen-Probe, San Diego, CA) specimen transport medium. During pelvic 
examination, the physician collected one cervical specimen from each woman using a 
Wallach Papette (Wallach Surgical Devices, Inc., Millford, CT), which was then placed 
into PreservCyt® medium (Cytyc Corp., Marlborough, MA).  
 
Screening for STIs 
The physician-collected specimens were tested for chlamydia and gonorrhea with 
the APTIMA Combo 2 assay, for trichomonas with the APTIMA TV assay and for 
mycoplasma with the APTIMA research use only assay. The APTIMA assays comprise three 
main steps, namely target capture, transcription-mediated amplification (TMA) of the 
target, and finally target detection by hybridization with complementary probes linked to 
chemiluminescent labels.12 All assays were performed according to the manufacturer’s 
instructions, with technicians blinded to Pap smear or other study results.  
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Variables and Statistical Analyses 
Six STIs (chlamydia, gonorrhea, trichomonas, HIV, HPV and mycoplasma) were 
combined into 15 independent pairs of STIs and their individual association with the four 
other STIs was examined using Chi-squares, bivariate logistic regression and exact logistic 
regression (for models that did not converge). Only HIV and HPV co-infection was found 
to be significantly associated with trichomonas infection. This association was further 
analyzed using propensity scores. The associations between other combinations of three 
STIs could not be examined using this dataset due to inadequate power. 
The independent variable was HIV-HPV co-infection (being HIV-HPV positive is 
hereafter referred to as being treated or in the treatment group, and being HIV-HPV 
negative is hereafter referred to as being a control or in the control group). The dependent 
variable was having a trichomonas infection (positive/negative). The hypothesis was that 
HIV, HPV and trichomonas infections cluster in individuals. The direction of causation 
cannot be assessed in this cross-sectional study i.e. whether initially having HIV and HPV 
co-infection increases the risk for trichomonas infection or whether initially having 
trichomonas and HIV co-infection increases the risk for acquiring HPV infection. Covariate 
selection was done after reviewing the literature on risk factors for each of the STIs above.  
 Analysis of variance and Chi-Square tests were used to examine the differences and 
associations respectively, between women with no STI, one STI and those with two or 
more STIs. The propensity score (PS) 26-31, the probability of having concurrent HIV and 
HPV infection (i.e. the probability of being treated) given the selected covariates was 
estimated using logistic regression and machine learning methods- boosted classification 
and regression tree (bCART) and covariate balancing propensity score methods (CBPS). For 
the bCART model, the interaction depth was two and the number of trees was set at 
15,000. For the logistic regression model, including interaction and quadratic terms in the 
model did not improve balance and therefore the final model had no interaction or 
quadratic terms. Interaction terms were generated using the SAS %int2way macro. The 
Logistic regression PS estimation model displayed some sensitivity to over-
parameterization with covariates; chlamydia was therefore left out of these models but was 
included in the final generalized linear models during the final effect estimation. 
Propensity score application was done by weighting (stabilized inverse probability 
of treatment weight [SIPTW] and standardized mortality ratio weight [SMRW]), matching 
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with replacement and stratification. Regression adjustment with the PS as a covariate was 
not done 26 as the difference in the means of the treatment and control groups was greater 
than half of one standard deviation. 14   
Matching was done with the R “Match” package. 32 Treated subjects were matched 
on the logit of the propensity score (logistic and CBPS estimated propensity scores only) 
with a caliper of 0.25 standard deviation. For matching done on the logit of the PS 
estimated by logistic regression, 33 treated subjects were matched to 30 controls, while for 
the PS estimated by CBPS, 27 controls were found for 33 treated subjects.  Caliper sizes 
were adjusted between 0.10 and 0.25 but this did not significantly alter the match results.  
Stratification on the propensity score was done with both 5 equal strata and 5 
unequal strata. Unequal stratification worsened covariate balance and therefore was not 
used to estimate treatment effects. Five strata were chosen because they have been shown 
to remove up to 90% of bias.29 Across all models, covariate balance before and after 
balancing on the propensity score was assessed using standardized absolute mean 
differences (SAMD; Figures 2 & 3). 33 Tests of significance were not used given their 
dependence on sample size. The region of common support showed significant overlap 
between the treatment and control groups (Figure 1); hence, no trimming outside the 
region of common support was done.  
Crude and Propensity score adjusted treatment effects were obtained using logistic 
regression (crude) and generalized linear models (for weighting and stratification) 
respectively. The average treatment effect in the treated [ATT], which was the effect of 
having HIV-HPV co-infection on trichomoniasis among those who tested positive for 
trichomoniasis, and the average treatment effect [ATE] among the whole population of 
treated and untreated (i.e. those who were trichomonas positive and those were 
trichomonas negative) were estimated from the PS weighted models. Treatment effect 
estimates from matching are among those who are trichomonas positive [ATT] while the 
estimates from stratification are among the whole population of trichomonas positive and 
negative women [ATE]. Weights were truncated at weight percentile pairs of 0 & 100, 5 & 
95, 10 & 90, 25 & 75, 50 & 50 and outcome models for the effect of HIV-HPV co-infection 
on trichomoniasis were run for each pair of weights. Sensitivity analysis 34 for unmeasured 
confounding was done for the matched treatment effect estimates. All analyses were done 
with SAS version 9.4 and R version 3.1.2.  
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Results 
Participant Characteristics 
 The average age of the respondents was 29.5 years (range 18-48 years) and the 
mean age at sexual debut was 16.2 years. The women had an average of 7.8 years of 
education and 3.1 clients per day. More than two in five women were single but most had 
regular sex partners (71.6%). Only 25.5% said they always used condoms at every sexual 
intercourse. Almost 80% of the women practiced douching and alcohol use was very 
common (83.8%). There were marginally significant differences in the age and number of 
daily clients among with women with different numbers of STIs (Table 1). 
 
Sexually Transmitted Infections 
 Twenty-five women (7.5%) were positive for trichomonas infection. Infection with 
HPV was the most prevalent among the six STIs (25.3%) and 24.0% were seropositive for 
HIV. Chlamydia (3.9%) and gonorrhea (2.1%) infections were uncommon and 44 women 
(13.2%) were positive for infection with mycoplasma. Women with trichomonas infection 
were significantly more likely to test positive for chlamydia infection (Table 1). 
 Forty-seven women (14.1%) had two concurrent STIs, the most frequent 
combination of which was HIV and HPV co-infection (33 women) and HPV and 
mycoplasma co-infection (17 women). Only 19 women had three concurrent STIs (Table 
2) On bivariate analyses, HIV and HPV con-infection was significantly associated with 
trichomonas infection (p<0.05; not shown in table). 
 
Association between HIV, HPV and Trichomonas Infections 
The propensity score- the probability of having HIV and HPV co-infection given the 
measured covariates, was estimated for the treatment and control groups (Figure 1). There 
was a significant overlap between those who were HIV-HPV positive and respondents who 
were HIV-HPV negative. The distribution of propensity score weights estimated from 
logistic regression, bCART and CBPS are shown in Table 3. The means of the inverse 
probability of treatment weights (IPTW) are all close to one. Stabilization of the IPTW 
estimated from logistic regression reduced the maximum weight from 80.6 to 8.0 (Table 3).  
While all three propensity score estimation methods improved covariate balance, 
the CBPS showed the greatest reduction in imbalance between the covariates (68.4% 
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reduction in average standardized absolute mean differences [ASAMD]) while boosting 
and logistic regression reduced the ASAMDs by 50.1% and 30.9% respectively. As 
expected, a similar trend was seen in the precision (standard deviations) of the SAMD for 
each covariate (Table 4; Figures 2 &3).  
Crude unadjusted and exact logistic regression models found significant 
associations between HIV-HPV co-infection and trichomoniasis. The ordinary logistic 
regression model that included all 19 covariates (adjusted) did not converge. However, 
treatment effect estimates from all propensity score methods of estimation (logistic, bCART 
and CBPS) and application (stratification, weighting and matching) showed no significant 
association between HIV, HPV and trichomoniasis. All three methods of propensity score 
estimation produced similar estimands and standard errors. ATE weighted logistic 
regression and stratification estimates were closest to the null value. Progressive weight 
truncation did not significantly change the treatment effect estimates. Sensitivity analysis 
for unmeasured confounding found that an unmeasured confounder would need to predict 
treatment assignment 1.30 times more frequently than the strongest measured confounder 
to qualitatively alter our findings.  
 
Correlates of Multiple Sexually Transmitted Infections 
 On regression adjustment, none of the covariates significantly predicted having two 
or more concurrent STIs. A higher number of clients per day was however marginally 
associated with having two or more STIs (p=0.08; not shown in table). 
 
 
Discussion 
The prevalence of the different STIs in this study are probably higher than those in 
the general population, given that these are female sex workers who are more likely to 
engage in higher risk sexual activity. Despite this, this study found that multiple concurrent 
STIs are uncommon. This is similar to findings by Miller et al and Kibur et al, who found 
that concurrent seropositivity for multiple STIs is not common. 22,23 
Secondly, we find no evidence that HIV, HPV and trichomoniasis infections cluster 
in women. Although there are no studies to contrast our findings with, until larger cross-
sectional cohorts are used to validate these findings, it may be plausible not to test or 
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presumptively treat HPV-HIV positive women for trichomoniasis in resource-limited 
settings. This finding should also be interpreted with caution, as temporal relations 
between these three STIs have not yet been ascertained and it is possible that the order of 
acquisition of the first two infections may influence the risk of acquiring a third. 
Also, propensity score methods were less sensitive to over-parameterization 
compared to the traditional regression method, which did not converge with all measured 
covariates in the model. Logistic regression may therefore not be an appropriate choice 
when the number of events per confounder are fewer than eight. 24 Exact logistic regression 
35, which is a reasonable alternative in this case, is a memory-intensive iterative process 
that is more likely to fail as the number of covariates increase. While PS methods are 
generally not considered superior to traditional covariance adjustment methods 36, this 
study is one of the few where results from traditional regression methods and PS 
qualitatively differ. In addition, propensity scoring allows for the assessment of covariate 
balance, a good approximation for how ‘exchangeable’ individuals in the treatment and 
control groups are. These may be compelling reasons why the use of PS should be 
considered for rare outcomes in maternal and child health where research findings often 
have public health implications. 
An obvious limitation to this study is that the data ‘selects’ the particular STIs 
between which associations can be tested. Also, temporality in the order of STI acquisition, 
which may influence the risk of additional infections in either direction cannot be assessed 
using cross-sectional data. Our matched estimates also show some sensitivity to 
unmeasured confounding, which may arise from prior self-medication with antibiotics 
among respondents, thereby altering the pattern of positivity to bacterial STIs. 
  
 
Conclusions 
 Multiple STIs are uncommon but may be associated with significant morbidity from 
missed screening and treatment opportunities. This is the first study to examine the 
clustering of multiple STIs at the individual level and although we could only examine the 
association between one set of three STIs and failed to find an association, significant cost 
savings and resource conservation can result from a reduction in the number of 
unnecessary screening and medication for trichomonas offered to women with HIV-HPV 
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co-infection. The development of clinical guidelines and treatment algorithms will also 
depend on epidemiological studies on the clustering of STIs. HIV, HPV and trichomonas 
infections do not seem to cluster in women and there seems to be no significant 
demographic or behavioral predictor of multiple STIs in women. Our study findings should 
be interpreted in the light of the data limitations and may benefit from validation with data 
from larger samples of women. 
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Appendix: Tables and Figures 
Table 1: Demographic and Behavioral Characteristics of Female Sex Workers in Korogocho, Kenya 
Characteristic Total  
(n=334) 
No STI  
(n=152) 
One STIs 
(n=116) 
Two or more 
STIs (n=66) 
Chlamydia 
   Positive 
   Negative 
 
13 (3.9%) 
321 (96.1%) 
 
0 (0.0%)*** 
152 (100.0%) 
 
4 (3.5%) 
112 (96.6%) 
 
9 (13.6%) 
57 (86.4%) 
Gonorrhea 
   Positive 
   Negative 
 
7 (2.10%) 
327 (97.90%) 
 
0 (0.0%)** 
152 (100.0%) 
 
3 (2.6%) 
113 (97.4%) 
 
4 (6.1%) 
62 (93.9%) 
Mycoplasma 
   Positive 
   Negative 
 
44 (13.2%) 
290 (86.8%) 
 
0 (0.0%)*** 
152 (100.0%) 
 
19 (16.4%) 
97 (83.6%) 
 
25 (37.9%) 
41 (62.1%) 
Trichomoniasis 
   Positive 
   Negative 
 
25 (7.5%) 
309 (92.5%) 
 
0 (0.0%)*** 
152 (100.0%) 
 
6 (5.2%) 
110 (94.8%) 
 
19 (28.8%) 
47 (71.2%) 
Human Papillomavirus (HPV) 
   Positive 
   Negative 
 
98 (2.3%) 
236 (70.7%) 
 
0 (0.0%)*** 
152 (100.0%) 
 
46 (39.7%) 
70 (60.3%) 
 
52 (78.8%) 
14 (21.2%) 
HIV Status 
   Positive 
   Negative 
 
80 (24.0%) 
254 (76.1%) 
 
0 (0.0%)*** 
152 (100.0%) 
 
38 (32.8%) 
78 (67.2%) 
 
42 (63.6%) 
24 (36.4%) 
Age (years) 29.5 ± 6.4 29.0 ± 5.9* 30.6 ± 7.3 28.6 ± 5.7 
Duration of Female Sex Work (years) 5.4 ± 4.0 6.0 ± 3.8 5.3 ± 3.7 5.3 ± 4.8 
Age at Sexual Debut (years) 16.2 ± 2.3 16.3 ± 2.2 16.3 ± 2.5 15.9 ± 2.0 
Completed School Years  7.8 ± 2.5 7.8 ± 2.4 8.0 ± 2.4 7.3 ± 3.0 
Charge per Sexual Act (Kenyan Shilling) 310.0 ± 373.1 320.4 ± 325.8 300 ± 481.0 303.8 ± 238.2 
Monthly Income from Sex work (Kenyan Shilling) 5238.6 ± 5256.0 5465.5 ± 6312.7 4790.1 ± 3996.8 5504.6 ± 4487.9 
Clients per day 3.1 ± 1.2 3.1 ± 1.2* 3.3 ± 1.3 2.9 ± 1.2 
Clients per week 12.0 ± 6.3* 11.7 ± 6.0 12.4 ± 6.8 11.8 ± 6.0 
Parity 2.7 ± 1.6 2.6 ± 1.5 2.7 ± 1.5 2.9 ± 2.1 
Marital Status 
   Single 
   Currently/Previously Married/Cohabiting 
 
148 (44.31%) 
186 (55.69%) 
 
69 (45.4%) 
83 (54.6%) 
 
47 (40.5%) 
69 (59.5%) 
 
32 (48.5%) 
34 (51.5%) 
Condom use 
   Always 
   Not always 
 
84 (25.2%) 
250 (74.9%) 
 
38 (25.0%) 
114 (75.0%) 
 
31 (26.7%) 
85 (73.3%) 
 
15 (22.7%) 
51 (77.3%) 
Has a Regular Client/Partner 
   Yes 
   No 
 
239 (71.6%) 
95 (28.4%) 
 
109 (71.7%) 
43 (28.3%) 
 
89 (76.7%) 
27 (23.3%) 
 
41 (62.1%) 
25 (37.9%) 
Ever Used Hormonal Contraceptives 
   Yes 
   No 
 
146 (43.7%) 
188 (56.3%) 
 
69 (45.4%) 
83 (54.6%) 
 
53 (45.7%) 
63 (54.3%) 
 
24 (36.4%) 
42 (63.6%) 
Ever Douched 
   Yes 
   No 
 
257 (77.0%) 
77 (23.1%) 
 
116 (76.3%) 
36 (23.7%) 
 
88 (75.9%) 
28 (24.1%) 
 
53 (80.3%) 
13 (19.7%) 
Ever Used Tobacco 
   Yes 
   No 
 
149 (44.6%) 
185 (55.4%) 
 
65 (42.8%) 
87 (57.2%) 
 
48 (41.4%) 
68 (58.6%) 
 
36 (54.6%) 
30 (45.5%) 
Ever Used Alcohol 
   Yes 
   No 
 
280 (83.8%) 
54 (16.2%) 
 
130 (85.5%) 
22 (14.5%) 
 
93 (80.2%) 
23 (19.8%) 
 
57 (86.4%) 
9 (13.6%) 
Ever Used Drugs 
   Yes 
   No 
 
71 (21.3%) 
263 (78.7%) 
 
32 (21.1%) 
120 (79.0%) 
 
26 (22.4%) 
90 (77.6%) 
 
13 (19.7%) 
53 (80.3%) 
Note: *p<0.10, **p<0.05, ***p<0.001; 1 Kenyan Shilling=$0.011; Drugs refer to illicit drugs not prescription  
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Table 2: Number of Concurrent Sexually Transmitted Infections among Female Sex Workers in 
Korogocho, Kenya 
Number of Concurrent STIs Number (Percentage) 
None 152 (45.5%) 
One 116 (34.7%) 
Two 47 (14.1%) 
Three 19 (5.7%) 
  Note: STIs are HIV, HPV, mycoplasma, trichomonas, chlamydia and gonorrhea 
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Table 3: Weight Distribution by Propensity Score estimation method 
 IPTW SMRW 
 Mean Max Mean Max 
Logistic Regression 1.01* 7.96* 0.19 1.00 
Boosted CART 0.93 1.47 0.13 1.00 
CBPS 0.99 3.46 0.20 1.00 
Notes:  i. IPTW- Inverse probability of treatment weight 
 ii. SMWR- Standardized mortality ratio weight 
 iii. *Weight for logistic model is stabilized 
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Table 4: Weighted and Unweighted Covariates before and after balancing on Propensity Scores 
(bCART only shown) 
Covariate Unweighted  bCART Weighted*  
 Treated  
(HIV-HPV 
positive) 
Controls  
(HIV-HPV 
Negative) 
SAMD Treated  
(HIV-HPV 
positive) 
Controls 
(HIV-HPV 
Negative) 
SAMD 
Age 30.4 ± 5.3 29.4 ± 6.5 0.1849 28.6 ± 5.5 29.4 ± 6.4 0.1515 
Age at Sexual Debut 15.8 ± 1.9 16.3 ± 2.3 0.2649 16.1 ± 1.87 16.3 ± 2.3 0.0945 
Completed School Years  6.4 ± 3.1 7.9 ± 2.4 0.4913 7.4 ± 2.3 7.9 ± 2.4 0.2148 
Duration of Prostitution 6.5 ± 4.3 5.3 ± 3.9 0.2770 5.1 ± 3.5 5.4 ± 4.0 0.0718 
Charge per sex 245.5 ± 164.1 317.1 ± 388.7 0.4366 265.8 ± 176.6 314.5 ± 383.4 0.2715 
Monthly Income from Sex work 5424.2 ± 5008.5 5218.3 ± 5290.0 0.0411 5423.4 ± 4901.4 5218.2 ± 5274.1 0.0412 
Clients per day 2.9 ± 1.2 3.2 ± 1.2 0.2560 3.0 ± 1.3 3.2 ± 1.2 0.1051 
Clients per week 12.0 ± 6.6 12.0 ± 6.3 0.0011 12.0 ± 7.0 11.9 ± 6.2 0.0057 
Parity 3.3 ± 2.0 2.7 ± 1.6 0.3117 2.8 ± 1.5 2.7 ± 1.6 0.0733 
Marital Status 0.7 ± 0.5 0.5 ± 0.5 0.3331 0.6 ± 0.5 0.6 ± 0.5 0.1005 
Condom use 0.2 ± 0.4 0.3 ± 0.4 0.0231 0.2 ± 0.4 0.3 ± 0.4 0.0482 
Has a Regular Client/Partner 0.6 ± 0.5 0.7 ± 0.4 0.3733 0.7 ± 0.5 0.7 ± 0.4 0.0922 
Hormonal Contraceptive use 0.3 ± 0.5 0.5 ± 0.5 0.2406 0.4 ± 0.5 0.5 ± 0.5 0.0217 
Douche 0.9 ± 0.4 0.8 ± 0.4 0.2408 0.9 ± 0.4 0.8 ± 0.4 0.2551 
Tobacco Use 0.6 ± 0.5 0.4 ± 0.5 0.4322 0.6 ± 0.5 0.4 ± 0.5 0.2642 
Alcohol Use 0.8 ± 0.4 0.8 ± 0.4 0.1348 0.8 ± 0.4 0.8 ± 0.4 0.0112 
Drug use/abuse 0.2 ± 0.4 0.2 ± 0.4 0.0761 0.2 ± 0.4 0.2 ± 0.4 0.0660 
Mycoplasma 0.2 ± 0.4 0.1 ± 0.3 0.1419 0.2 ± 0.4 0.1 ± 0.3 0.2143 
Gonorrhea 0.1 ± 0.2 0.02 ± 0.13 0.1816 0.04 ± 0.20 0.02 ± 0.13 0.1158 
ASAMD   0.2338   0.1168 
Notes:  i. bCART- Boosted classification and regression trees 
ii. SAMD- Standardized absolute mean difference 
iii. ASAMD- Average standardized absolute mean difference  
iv. *Weights are inverse probability of treatment weights; ASAMD- Average standardized absolute 
mean difference 
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Table 5: Treatment Effect Estimates for the effect of HIV-HPV Co-infection on Trichomoniasis 
PS Estimation Method Unweighted Coefficient  
Weighting (ATE) 
Effect Estimate 
Weighting (ATT) 
Effect Estimate 
Matching (ATT) 
Effect Estimate 
Stratification 
Crude Logistic Regression 0.119 ± 0.048*     
Exact Logistic Regression 1.230 ± 0.511*     
PS Logistic  0.086 ± 0.069 0.135 ± 0.070 0.100 ± 0.065 0.051 ± 0.061 
PS CBPS  0.137 ± 0.082 0.129 ± 0.071 0.130 ± 0.068  
PS bCART  0.121 ± 0.072 0.135 ± 0.069   
*Notes: i. PS- Propensity Score 
 ii. ATE- Average treatment effect in the whole population 
 iii. ATT- Average treatment effect in the treated 
iv. CBPS- Covariate balancing propensity score 
v. bCART- Boosted classification and regression tree 
vi. *p<0.05; Estimates are Coefficients ± Standard errors 
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Figure 1: Kernel Density Plot of Propensity Scores by HIV-HPV Co-infection Status 
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Figure 2: Standardized Absolute Mean Differences between Covariates by Propensity Score 
Estimation Method 
 
 
Notes:  i. bCART- Boosted classification and regression tree 
 ii. CBPS- Covariate balancing propensity score 
 
 
 
 
 
 
 
	   23	  
 
 
 
 
Figure 3: Standardized Absolute Mean Differences after Weighting with the Propensity Score 
(Boosted Classification and Regression Tree Weights) 
 
 
 
 
 
